New drug 'Unmasks' cancer cells to immune system in early trial
NCT ID NCT07583914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack them. The main goal is to check safety and find the right dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?